Delgocitinib cream for moderate to severe chronic hand eczema in everyday care
Observes how delgocitinib cream works and how safe it is in adults.
Plain-language title generated from the registry record
Registry title: Real-World Evidence: Effectiveness and Safety of Chronic Hand Eczema Treatment With Delgocitinib Cream
Key facts
- Where
- Neu-Isenburg, GermanySee the site
Where in Germany
- LEO PharmaNeu-Isenburg, GermanyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- LEO Pharma
- Trial code
- NCT07603193
- Record updated
- 22 May 2026
- Original description
The goal of this non-interventional study is to assess changes in the signs and symptoms of Chronic Hand Eczema (CHE), as well as the safety profile and use of delgocitinib cream in routine clinical practice, over a 52-week observation period.Read full original descriptionShow less
Prospective, Non-interventional, Multicenter Real-world Evidence Study on Effectiveness and Safety of Treatment of Patients With Moderate to Severe Chronic Hand Eczema With Delgocitinib Cream (20mg/g)
The goal of this non-interventional study is to assess changes in the signs and symptoms of Chronic Hand Eczema (CHE), as well as the safety profile and use of delgocitinib cream in routine clinical practice, over a 52-week observation period.
The main question it aims to answer is:
Does delgocitinib cream show effectiveness in routine clinical practice in adult patients with moderate to severe Chronic Hand Eczema (CHE), as measured by achievement of a modified Physician Global Assessment (mPGA) score of 0 or 1?
The decision to prescribe delgocitinib cream is made by the treating physician, as part of the participant's routine medical care for CHE.
Inclusion: Written informed consent to participate in this study and for collecting and analysing medical data pertinent to the study objectives; Age ≥18 years; Patients diagnosed with CHE who are eligible for treatment with delgocitinib cream as per the physician's clinical discretion.
Exclusion: Previous enrolment in this non-interventional study; Previous treatment with delgocitinib cream; Currently enrolled in an interventional clinical trial, or have participated in an interventional clinical trial in the past year from the date of enrolment.